Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.5023
0.0511.62%
At close: -
$0.4899
-0.01-2.47%
After Hours: Jun 18, 7:56 PM EDT
Comments
Loading...
CARISMA Therapeutics Analyst Ratings and Price Targets | NASDAQ:CARM | Benzinga
CARISMA Therapeutics Inc has a consensus price target of $7.34 based on the ratings of 7 analysts. The high is $24 issued by EF Hutton on November 7, 2024. The low is $0.7 issued by Evercore ISI Group on December 11, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital on April 1, 2025, January 17, 2025, and January 13, 2025, respectively. With an average price target of $8.33 between D. Boral Capital, there's an implied 1601.03% upside for CARISMA Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
Baird
Evercore ISI Group
EF Hutton
Capital One
1calculated from analyst ratings
Analyst Ratings for CARISMA Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/01/2025 | Buy Now | 104.12% | D. Boral Capital | Jason Kolbert54% | $12 → $1 | Maintains | Buy | Get Alert |
| 01/17/2025 | Buy Now | 2349.48% | D. Boral Capital | Jason Kolbert54% | $12 → $12 | Maintains | Buy | Get Alert |
| 01/13/2025 | Buy Now | 2349.48% | D. Boral Capital | Jason Kolbert54% | $12 → $12 | Maintains | Buy | Get Alert |
| 12/16/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor46% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/12/2024 | Buy Now | 2349.48% | D. Boral Capital | Jason Kolbert54% | $12 → $12 | Maintains | Buy | Get Alert |
| 12/12/2024 | Buy Now | 104.12% | Baird | Jack Allen 37% | $10 → $1 | Downgrade | Outperform → Neutral | Get Alert |
| 12/11/2024 | Buy Now | 42.89% | Evercore ISI Group | Liisa Bayko70% | $4 → $0.7 | Downgrade | Outperform → In-Line | Get Alert |
| 12/10/2024 | Buy Now | — | BTIG | Justin Zelin41% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/09/2024 | Buy Now | 2349.48% | D. Boral Capital | Jason Kolbert54% | $24 → $12 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 920.62% | HC Wainwright & Co. | Mitchell Kapoor46% | $8 → $5 | Maintains | Buy | Get Alert |
| 11/18/2024 | Buy Now | 4798.96% | D. Boral Capital | Jason Kolbert54% | $24 → $24 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | 4798.96% | D. Boral Capital | Jason Kolbert54% | $24 → $24 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 4798.96% | EF Hutton | Jason Kolbert54% | $24 → $24 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 4798.96% | EF Hutton | Jason Kolbert54% | → $24 | Initiates | → Buy | Get Alert |
| 06/28/2024 | Buy Now | 1532.99% | HC Wainwright & Co. | Mitchell Kapoor46% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 1532.99% | HC Wainwright & Co. | Mitchell Kapoor46% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 1532.99% | HC Wainwright & Co. | Mitchell Kapoor46% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 1532.99% | HC Wainwright & Co. | Mitchell Kapoor46% | $9 → $8 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | 1124.74% | BTIG | Justin Zelin41% | → $6 | Initiates | → Buy | Get Alert |
| 04/02/2024 | Buy Now | 1737.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $11 → $9 | Maintains | Buy | Get Alert |
| 11/29/2023 | Buy Now | 2145.36% | HC Wainwright & Co. | Mitchell Kapoor46% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | Buy Now | 1941.23% | Capital One | Naureen Quibria19% | → $10 | Initiates | → Overweight | Get Alert |
| 09/06/2023 | Buy Now | 2145.36% | HC Wainwright & Co. | Mitchell Kapoor46% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 2145.36% | HC Wainwright & Co. | Mitchell Kapoor46% | $10 → $11 | Maintains | Buy | Get Alert |
| 07/06/2023 | Buy Now | 2349.48% | Evercore ISI Group | Liisa Bayko70% | → $12 | Initiates | → Outperform | Get Alert |
| 06/29/2023 | Buy Now | 1941.23% | HC Wainwright & Co. | Mitchell Kapoor46% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | 1941.23% | Baird | Jack Allen 37% | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 05/24/2023 | Buy Now | 1941.23% | HC Wainwright & Co. | Mitchell Kapoor46% | → $10 | Initiates | → Buy | Get Alert |
| 04/14/2023 | Buy Now | 1941.23% | Baird | Jack Allen 37% | → $10 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for CARISMA Therapeutics (CARM) stock?
The latest price target for CARISMA Therapeutics (NASDAQ:CARM) was reported by D. Boral Capital on April 1, 2025. The analyst firm set a price target for $1.00 expecting CARM to rise to within 12 months (a possible 104.12% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CARISMA Therapeutics (CARM)?
The latest analyst rating for CARISMA Therapeutics (NASDAQ:CARM) was provided by D. Boral Capital, and CARISMA Therapeutics maintained their buy rating.
When was the last upgrade for CARISMA Therapeutics (CARM)?
There is no last upgrade for CARISMA Therapeutics
When was the last downgrade for CARISMA Therapeutics (CARM)?
The last downgrade for CARISMA Therapeutics Inc happened on December 16, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for CARISMA Therapeutics Inc.
When is the next analyst rating going to be posted or updated for CARISMA Therapeutics (CARM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CARISMA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CARISMA Therapeutics was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.
Is the Analyst Rating CARISMA Therapeutics (CARM) correct?
While ratings are subjective and will change, the latest CARISMA Therapeutics (CARM) rating was a maintained with a price target of $12.00 to $1.00. The current price CARISMA Therapeutics (CARM) is trading at is $0.49, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
